Administration of an antibody that specifically binds IL-1α is useful for treating cachexia and increasing the lifespan of a subject suffering from cachexia.

The present invention comprises a composition of β-Hydroxy-β-Methylbutyrate (HMB) with or without Vitamin D to enhance muscle strength and physical functionality, even in individuals not engaged in an exercise training program wherein the enhancements in muscle strength and physical functionality are similar to those seen with exercise.

The present invention comprises a composition of β-Hydroxy-β-Methylbutyrate (HMB) with or without Vitamin D to enhance muscle strength and physical functionality, even in individuals not engaged in an exercise training program wherein the enhancements in muscle strength and physical functionality are similar to those seen with exercise.

The present disclosure provides antibodies that specifically bind to and block signaling by ACVR2A, i.e., ACVR2A but not ACVR2B, as well as methods for using the same. The antibodies may be used for the treatment of a number of conditions associated with muscle atrophy, as well as other conditions.

The present disclosure provides antibodies that specifically bind to and block signaling by ACVR2A, i.e., ACVR2A but not ACVR2B, as well as methods for using the same. The antibodies may be used for the treatment of a number of conditions associated with muscle atrophy, as well as other conditions.

A composition including at least one phytoecdysone or at least one semi-synthetic derivative of a phytoecdysone, for use in mammals for preventing the loss of muscle strength during immobilisation. More particularly, a composition for use that includes 20-hydroxyecdysone or a semi-synthetic derivative of 20-hydroxyecdysone. Moreover, the composition for use includes a compound of general formula (I).

A composition including at least one phytoecdysone or at least one semi-synthetic derivative of a phytoecdysone, for use in mammals for preventing the loss of muscle strength during immobilisation. More particularly, a composition for use that includes 20-hydroxyecdysone or a semi-synthetic derivative of 20-hydroxyecdysone. Moreover, the composition for use includes a compound of general formula (I).

Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating Facioscapulohumeral muscular dystrophy.

Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating Facioscapulohumeral muscular dystrophy.

The invention relates generally to the field of medical treatment. More particularly, the invention relates to treating a subject in order to reduce levels of triglycerides or cortisol by the administration of pharmaceutical formulations.